Organization
Biocad
25 clinical trials
1 abstract
Clinical trial
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex® in Subjects With Relapsed and Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
An Open-Label Two-Stage Trial of the Safety, Pharmacodynamics, Biodistribution, Immunogenicity and Efficacy of Single-Dose Administration of ANB-010 in Subjects With Hemophilia AStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
An Open-Label, Non-Comparative Clinical Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene (ANB-004 (JSC BIOCAD, Russia)) After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular AtrophyStatus: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
An Open-Label, Non-controlled Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of Single Escalating Doses of BCD-180 (JSC BIOCAD, Russia) in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-09-30
Clinical trial
International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) PatientsStatus: Completed, Estimated PCD: 2014-11-01
Clinical trial
A Double-Blind Placebo-Controlled Comparative Randomized Clinical Study of the Efficacy and Safety of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid ArthritisStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Multicenter Open-label Study of the Efficacy, Pharmacokinetica and Safety of Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-06-01
Clinical trial
International Multicenter Double-Blind Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) And BCD-100 (Anti-PD-1) Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple SclerosisStatus: Completed, Estimated PCD: 2016-11-21
Clinical trial
A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy VolunteersStatus: Active (not recruiting), Estimated PCD: 2023-04-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Adaptive, Seamless Phase I / II Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5-RBD-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)Status: Terminated, Estimated PCD: 2022-04-18
Clinical trial
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the SkinStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing SpondylitisStatus: Active (not recruiting), Estimated PCD: 2018-12-24
Clinical trial
An Open-label, Non-comparative, Single Dose-Escalation Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia BStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of Divozilimab in Patients With Systemic SclerodermaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
An Open-Label, Dose-Escalation, Non-comparative Clinical Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-245 (JSC BIOCAD, Russia) Administered Intravenously to Subjects With NeuroblastomaStatus: Recruiting, Estimated PCD: 2023-06-01
Clinical trial
A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast CancerStatus: Recruiting, Estimated PCD: 2024-01-22
Clinical trial
An International, Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2025-12-01
Clinical trial
A Randomized Study of the Efficacy and Safety of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) Versus Standard Adjuvant Therapy With Pembrolizumab in Patients With Resectable Stage III Skin Melanoma.Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum DisordersStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Randomized, Double-Blind, Comparative Clinical Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Single Intravenous Infusion of BCD-264 and Darzalex® in Healthy VolunteersStatus: Completed, Estimated PCD: 2023-08-15
Clinical trial
A Multicenter, Double-Blind, Randomized Clinical Study to Evaluate the Pharmacokinetics and Safety of BCD-201 (JSC BIOCAD, Russia) and Keytruda® in Patients With Different Advanced MalignanciesStatus: Active (not recruiting), Estimated PCD: 2022-06-21
Clinical trial
A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients With Unresectable or Metastatic MelanomaStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Clinical Study of the Efficacy and Safety of BCD-180 in Patients With Active Axial SpondyloarthritisStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Abstract
Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.Org: Biocad, AV Medical Group, Saint-Petersburg, Russian Federation, Novaya klinika, Modern Medical Technologies Clinic, Altai Regional Oncology Center,